A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea

Palliat Med. 2003 Dec;17(8):659-63. doi: 10.1191/0269216303pm826oa.


Context: The symptomatic benefits of oxygen in patients with cancer who have nonhypoxic dyspnea are not well defined.

Objective: To determine whether or not oxygen is more effective than air in decreasing dyspnea and fatigue and increasing distance walked during a 6-minute walk test.

Patients and methods: Patients with advanced cancer who had no severe hypoxemia (i.e., had an O2 saturation level of > or = 90%) at rest and had a dyspnea intensity of > or = 3 on a scale of 0-10 (0 = no shortness of breath, 10 = worst imaginable shortness of breath) were recruited from an outpatient thoracic clinic at a comprehensive cancer center. This was a double-blind, randomized crossover trial. Supplemental oxygen or air (5 L/min) was administered via nasal cannula during a 6-minute walk test. The outcome measures were dyspnea at 3 and 6 minutes, fatigue at 6 minutes, and distance walked. We also measured oxygen saturation levels at baseline, before second treatment phase, and at the end of study.

Results: In 33 evaluable patients (31 with lung cancer), no significant differences between treatment groups were observed in dyspnea, fatigue, or distance walked (dyspnea at 3 minutes: P = 0.61; dyspnea, fatigue, and distance walked at 6 minutes: P = 0.81, 0.37, and 0.23, respectively).

Conclusions: Currently, the routine use of supplemental oxygen for dyspnea during exercise in this patient population cannot be recommended.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Air*
  • Blood Gas Analysis
  • Chronic Disease
  • Cross-Over Studies
  • Double-Blind Method
  • Dyspnea / prevention & control*
  • Exercise Test
  • Fatigue / prevention & control
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / complications*
  • Oxygen Inhalation Therapy / methods*